Non-Hodgkin Lymphoma Following Temozolomide

被引：11

作者：

Sharma, Atul ^{[1
]}

Gupta, Deepak ^{[1
]}

Mohanti, B. K. ^{[2
]}

Thulkar, Sanjay ^{[3
]}

Dwary, Amit ^{[1
]}

Goyal, Shikha ^{[2
]}

Muzumder, Sandeep ^{[2
]}

Das, Prasenjit ^{[4
]}

机构：

[1] All India Inst Med Sci, Dr BRA IRCH, Dept Med Oncol, New Delhi 110029, India

[2] All India Inst Med Sci, Dr BRA IRCH, Dept Radiat Oncol, New Delhi 110029, India

[3] All India Inst Med Sci, Dr BRA IRCH, Dept Radiodiag, New Delhi 110029, India

[4] All India Inst Med Sci, Dr BRA IRCH, Dept Pathol, New Delhi 110029, India

来源：

PEDIATRIC BLOOD & CANCER | 2009年 / 53卷 / 04期

关键词：

glioblastoma multiforme; temozolomide; second malignancy; non-Hodgkin lymphoma;

D O I：

10.1002/pbc.22090

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Temozolomide (TMZ) is an oral alkylating agent with significant activity against glioblastoma multiforme (GBM) and melanoma. It increases survival by 2.5 months when used in combination with radiotherapy as an adjuvant therapy in GBM. Secondary MDS/AML or non-Hodgkin lymphoma attributed to TMZ exposure has been reported. We report a case of non-Hodgkin lymphoma secondary to temozolomide in a 20-year-old female who was treated for GBM with concurrent TMZ and radiotherapy. She developed lymphoma 2 months after completing chemoradiotherapy. Although she was treated with combination chemotherapy for lymphoma, she died of progressive GBM. Pediatr Blood Cancer 2009;53: 661-662. (C) 2009 Wiley-Lis, Inc.

引用

页码：661 / 662

页数：2

共 50 条

[31] Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma
Kathleen M. McCarten
Helen R. Nadel
Barry L. Shulkin
Steve Y. Cho
Pediatric Radiology, 2019, 49 : 1545 - 1564
[32] Risk and outcome of non-Hodgkin lymphoma among classical Hodgkin lymphoma survivors
Xavier, Ana C.
Armeson, Kent E.
Hill, Elizabeth G.
Costa, Luciano J.
CANCER, 2013, 119 (18) : 3385 - 3392
[33] Non-Hodgkin lymphoma in the Far East: review of 730 cases from the international non-Hodgkin lymphoma classification project
Anamarija M. Perry
Jacques Diebold
Bharat N. Nathwani
Kenneth A. MacLennan
Hans K. Müller-Hermelink
Martin Bast
Eugene Boilesen
James O. Armitage
Dennis D. Weisenburger
Annals of Hematology, 2016, 95 : 245 - 251
[34] Non-Hodgkin lymphoma in Southern Africa: review of 487 cases from The International Non-Hodgkin Lymphoma Classification Project
Perry, Anamarija M.
Perner, Yvonne
Diebold, Jacques
Nathwani, Bharat N.
MacLennan, Kenneth A.
Mueller-Hermelink, Hans K.
Bast, Martin
Boilesen, Eugene
Armitage, James O.
Weisenburger, Dennis D.
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (05) : 716 - 723
[35] Non-Hodgkin lymphoma in the Far East: review of 730 cases from the international non-Hodgkin lymphoma classification project
Perry, Anamarija M.
Diebold, Jacques
Nathwani, Bharat N.
MacLennan, Kenneth A.
Mueller-Hermelink, Hans K.
Bast, Martin
Boilesen, Eugene
Armitage, James O.
Weisenburger, Dennis D.
ANNALS OF HEMATOLOGY, 2016, 95 (02) : 245 - 251
[36] Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy
Grover, Natalie S.
Park, Steven I.
PHARMACEUTICALS, 2015, 8 (03) : 607 - 636
[37] Second malignancy after treatment of childhood non-Hodgkin lymphoma
Leung, W
Sandlund, JT
Hudson, MM
Zhou, YM
Hancock, ML
Zhu, YP
Ribeiro, RC
Rubnitz, JE
Kun, LE
Razzouk, B
Evans, WE
Pui, CH
CANCER, 2001, 92 (07) : 1959 - 1966
[38] Clozapine is associated with an increased risk of Hodgkin and non-Hodgkin lymphoma
Frey, Connor
Etminan, Mahyar
LEUKEMIA & LYMPHOMA, 2025,
[39] New therapeutic strategies in non-Hodgkin lymphomas and Hodgkin lymphoma
Rossi, C.
Bastie, J. N.
REVUE DE MEDECINE INTERNE, 2019, 40 (04): : 246 - 254
[40] Diet and non-Hodgkin's lymphoma risk
Mozaheb, Zahra
Aledavood, Amir
Farzad, Farzaneh
PAN AFRICAN MEDICAL JOURNAL, 2012, 12

← 1 2 3 4 5 →